Advertisement
Advertisement
U.S. markets open in 1 hour 52 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Atara Biotherapeutics, Inc. (ATRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.6600+0.1800 (+4.02%)
At close: 04:00PM EST
4.6500 -0.01 (-0.21%)
Pre-Market: 07:31AM EST
Advertisement

Atara Biotherapeutics, Inc.

611 Gateway Boulevard
Suite 900
South San Francisco, CA 94080
United States
650 278 8930
https://www.atarabio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees340

Key Executives

NameTitlePayExercisedYear Born
Dr. Pascal Touchon D.V.M.Pres, CEO & Director1.11MN/A1963
Mr. Utpal Koppikar M.B.A.Exec. VP & CFO676.39kN/A1971
Mr. K. Amar MuruganSr. VP & Gen. Counsel611.76kN/A1975
Dr. Jakob Dupont M.D.Exec. VP and Global Head of R&D885.05k75.94k1965
Ms. Charlene BanardChief Technical OfficerN/AN/A1963
Dr. Anhco NguyenChief Scientific OfficerN/AN/A1973
Eric HyllengrenVP of Investor Relations & Fin.N/AN/AN/A
Kerry Beth DalyHead of Corp. CommunicationsN/AN/AN/A
Ms. Amie KrauseChief People OfficerN/AN/AN/A
Mr. Joseph NewellExec. VPN/AN/A1970
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Corporate Governance

Atara Biotherapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement